Altimmune, Inc. insider trading
Every open-market purchase and sale by Altimmune, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Altimmune, Inc.’s insiders pay?
From May 19, 2010 to August 13, 2026, 23 insiders reported 41 open-market purchases and 6 sales not made under a pre-set plan in Altimmune, Inc. Twelve months after each purchase was reported, the shares were −13.3% against the S&P 500 on average (median −32.3%), over 4 purchases with a full year of prices; 25% beat the index. After sales, the shares moved −66.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 29, 2020 into $6,486 by November 2, 2026, −6.5% a year. It held shares 40% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $21,827 (+12.9% a year), and held throughout $27,179 (+16.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Schaffer Derace L | Director | 11 | — | — | 1 | — | January 2, 2018 |
| Durso Jerome Benedict | President and CEO | 4 | — | — | 0 | — | August 13, 2026 |
| Drutz David | Director | 2 | — | — | 1 | −66.7% (1) | August 20, 2024 |
| Gill John | Director | 2 | — | — | 1 | — | April 6, 2026 |
| Weaver Gregory L | Chief Financial Officer | 3 | −60.7% (1) | 0% | 0 | — | April 1, 2026 |
| Pappajohn John | Director | 1 | — | — | 1 | — | May 27, 2011 |
| Prescott Group Capital Management, L.L.C. | 10% owner | 1 | — | — | 1 | — | December 9, 2016 |
| Richman Eric I | President and CEO | 2 | — | — | 0 | — | November 14, 2011 |
| Runge Jeffrey W. | Director | 2 | — | — | 0 | — | December 14, 2011 |
| Chang Linda L | SVP & CFO | 1 | — | — | 0 | — | November 18, 2011 |
| Eisenstadt Richard I | Chief Financial Officer | 1 | — | — | 0 | — | March 24, 2023 |
| Fuerst Thomas Richard | EVP, Chief Scientific Officer | 1 | — | — | 0 | — | November 14, 2011 |
| Garg Vipin K | President and CEO | 1 | — | — | 0 | — | September 5, 2019 |
| Harris Matthew Scott | Chief Medical Officer | 1 | — | — | 0 | — | March 23, 2023 |
| Karp Jordan P | SVP, General Counsel | 1 | — | — | 0 | — | November 14, 2011 |
| Pisano Wayne | Director | 1 | — | — | 0 | — | January 9, 2026 |
| Sayare Mitchel | Director | 1 | — | — | 0 | — | August 19, 2011 |
| Schafer Klaus | Director | 1 | −63.7% (1) | 0% | 0 | — | December 11, 2020 |
| Simon Nicholas J III and related entities | 10% owner | 1 | — | — | 0 | — | November 5, 2010 |
| St Peter Steven | Director | 1 | — | — | 0 | — | March 23, 2015 |
| Velocity Pharmaceutical Holdings LLC | 10% owner | 0 | — | — | 1 | — | May 18, 2020 |
| Vhcp Co-Investment Holdings II, LLC | 10% owner | 1 | +75.3% (1) | 100% | 0 | — | June 15, 2020 |
| Vhcp Management III, LLC | 10% owner | 1 | −3.9% (1) | 0% | 0 | — | May 28, 2020 |
When several insiders traded Altimmune, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Altimmune, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −18.8% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2020 | 2 buying | +13.3% | −18.8% | −48.9% |